Captopril ameliorates the decreased Na+,K+-ATPase activity in the retina of streptozotocin-induced diabetic rats

Investigative Ophthalmology and Visual Science

Volumn 37, Issue 8, 1996, Pages 1633-1641

  Ottlecz, Anna ^a   Bensaoula, Thouria ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

ACE; captopril; Na+,K+ ATPase; retina; streptozotocin diabetic rats

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; OUABAIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; HEART FAILURE; HYPERTENSION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STREPTOZOCIN DIABETES;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-BACTERIAL AGENTS; BLOOD GLUCOSE; CAPTOPRIL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; ENZYME INHIBITORS; ISOENZYMES; MALE; NA(+)-K(+)-EXCHANGING ATPASE; OUABAIN; PEPTIDYL-DIPEPTIDASE A; RANDOM ALLOCATION; RATS; RETINA; STREPTOZOCIN;

EID: 0029741677     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Larsen M, Hommel E, Parving H-H, Lund-Andersen H. Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graefe's Arch Clin Exp Ophthalmol. 1990;228:505-509.
2. Parving H-H. Impact of blood pressure and antihypertensive treatment on incipient and overt nephropathy, retinopathy, and endothelial permeability in diabetes mellitus. Diabetes Care. 1991;14:260-269.
3. Khadem J, Thomas CH, DuBovy S, Hasenyager J, Goldstick TK, Ernest JT. Hypertensive diabetics treated with angiotensin converting enzyme inhibitors develop less retinopathy. ARVO Abstracts. Invest Ophthalmol Vis Sci. 1994;35:1560.
4. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986;77:1925-1930.
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
6. Ido Y, Chang K, Allison WS, Tilton RG, Williamson JR. Angiotensin converting enzyme inhibitors ameliorate increased vascular leakage of albumin in eyes of diabetic rats. ARVO Abstracts. Invest Ophthalmol Vis Sci. 1991;32:1288.
7. Greene DA, Lattimer SA, Sima AAF. Sorbitol, phosphoinositides, and sodium-potassium ATPase in the pathogenesis of diabetic complications. N Engl J Med. 1987;316:599-606.
8. Frank RN. On the pathogenesis of diabetic retinopathy: A 1990 update. Ophthalmology. 1991;98:586-593.
9. Davis MD. Diabetic retinopathy. Diabetes Care. 1992; 15:1844-1874.
10. MacGregor LC, Matschinsky FM. Altered retinal metabolism in diabetes: II: Measurement of sodium-potassium ATPase and total sodium and potassium in individual retinal layers. J Biol Chem. 1986;261:4052-4058.
11. +-ATPase in rat aorta. Diabetes. 1991;40:1560-1563.
12. Ruderman NB, Williamson JR, Brownlee M. Glucose and diabetic vascular disease. FASEB J. 1992;6:2905-2914.
13. +-ATPase in diabetes: Streptozotocin-induced and Zucker diabetic fatty rats. Curr Eye Res. 1993;12:1111-1121.
14. Kern T, Kowluru RA, Engerman RL. Abnormalities of retinal metabolism in diabetes or galactosemia: AT-Pases and glutathione. Invest Ophthalmol Vis Sci. 1994;35:2962-2967.
15. Robison WG, Lovaer NM. Ocular lesions in animal models of human diabetes. In: Shafrir E, ed. Lessions from animal diabetes IV. London: Smith-Gordon; 1993:145-163.
16. Skou JC. Overview: The Na,K-pump. Methods Enzymol. 1988;156:1-25.
17. Stahl WL. The Na,K-ATPase of nervous tissue. Neurochem Int. 1986;72:1-10.
18. Lieberman L, Sastre A. Serum angiotensin-converting enzyme: Elevations in diabetes mellitus. Ann Intern Med. 1980;93:825-826.
19. Luetscher AJ, Kraemer FB, Wilson MD, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus: A marker of microvascular complications. N Engl J Med. 1985;312:1412-1417.
20. Duntas L, Keck FS, Haug C, et al. Serum angiotensin-converting enzyme activity and active renin plasma concentrations in insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1992;16:203-208.
21. Migdalis IN, Iliopoulou V, Kalogeropoulou K, Koutoulidis K, Samartzis M. Elevated serum levels of angiotensin-converting enzyme in patients with diabetic retinopathy. South Med J. 1990;83:425-427.
22. Yang HYT, Erdös EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta. 1970;214:374-376.
23. Erdös EG, Skidgel RA. The unusual substrate specificity and the distribution of human angiotensin I converting enzyme. Hypertension. 1986;8(suppl I):I34-I37.
24. Funakawa S, Okahara T, Imanishi M, Komoro T, Yamamoto K, Tochino Y. Renin-angiotensin system and prostacyclin biosynthesis in streptozotocin diabetic rats. Eur J Pharmacol. 1983;94:27-33.
25. Cassis LA. Down regulation of the renin-angiotensin system in streptozotocin-diabetic rats. Am J Physiol. 1992;262:E105-E109.
26. 3 ATPase in retina: Dependence on calcium and sodium. Invest Ophthalmol Vis Sci. 1977;16:1151-1154.
27. Erdös EG, Schulz WW, Gafford JT, Defendini R. Neutral metallo-endopeptidase in human male genital tract. Lab Invest. 1985;52:437-447.
28. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein. Anal Biochem. 1976;72:248-254.
29. +-ATPaSe of the photoreceptor: Selective expression of α3 and β2 isoforms. Exp Eye Res. 1990;51:553-564.
30. +-ATPase isoforms in retina and optic nerve. Eur J Neurosci. 1989;2:170-176.
31. Marks MJ, Seeds NW. Development of ion metabolism in reaggregated brain cell cultures. J Neurochem. 1982;38:101-111.
32. Atterwill CK, Reid J, Athayde CM. Effect of thyroid status on the development of the different molecular forms of Na,K-ATPase in rat brain. Mol Cell Endocrinol. 1985;40:149-158.
33. Lee T-S, MacGregor LC, Fluharty SJ, King GL. Differential regulation of protein kinase C and (Na,K)-adenosine triphosphatase activities by elevated glucose levels in retinal capillary endothelial cells. J Clin Invest. 1989;83:90-94.
34. Berweck S, Thieme H, Heibig H, et al. Effect of elevated glucose concentration on membrane voltage regulation in retinal capillary pericytes. Diabetes. 1993;42:1347-1350.
35. +-ATPase isoforms in the retina. Int Rev Cytol. 1992;133:151-185.
36. +-ATPase a subunit from rat brain. Biochemistry. 1986a;25:8125-8132.
37. Kirber WM, Nichols CW, Grimes PA, Winegrad AI, Laties AM. A permeability defect of the retinal pigment epithelium. Arch Ophthalmol. 1980;98:725-728.
38. Kowluru A, Kowluru RA, Yamazaki A. Functional alterations of G-proteins in diabetic rat retina: A possible explanation for the early visual abnormalities in diabetes mellitus. Diabetologia. 1992;35:624-631.
39. MacGregor LC, Matschinsky FM. Treatment with aldose reductase inhibitor or with myoinositol arrests deterioration of the electroretinogram of diabtic rats. J Clin Invest. 1985;76:887-889.
40. +-ATPase catalytic (α) subunits in the nerve of rats with streptozotocin-induced diabetes. J Neurochem. 1994;63:1782-1786.
41. Leong SF, Leung TKC. Diabetes induced by streptozotocin causes reduced Na,K-ATPase in the brain. Neurochem Res. 1991;16:1161-1165.
42. Danser AHJ, van den Dorpel MA, Deinum J, et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab. 1989;68:160-167.
43. Hallab B, Bled F, Ebran JM, et al. Elevated serum angiotensin converting enzyme activity in type I, insulin-dependent diabetic subjects with persistent microalbuminuria. Acta Diabetol. 1992;29:82-85.
44. Valentovic MA, Elliott CW, Ball JG. The effect of streptozotocin-induced diabetes and insulin treatment on angiotensin converting enzyme activity. Res Commun Chem Pathol Pharmacol 1987;58:27-39.
45. Schalekamp MADH. Renin-angiotensin system components and endothelial proteins as markers of diabetic microvascular disease. Clin Invest. 1993;71:S3-S6.
46. Fyhrquist F, Forslund T, Tikkanen I, Gronhagen-Riska C. Induction of angiotensin-converting enzyme in rat lung with captopril (SQ 14225). Eur J Pharmacol. 1980;67:473-475.
47. Chai SY, Perich R, Jackson B, Mendelsohn FAO, Johnston CI. Acute and chronic effects of angiotensin-converting enzyme inhibitors on tissue angiotensin-converting enzyme. Clin Exp Pharmacol Physiol. 1992; (suppl 19):7-12.
48. Kokubu T, Ueda E, Ono M, Kawabe T, Hayashi Y, Ran T. Effects of captopril (SQ 14, 225) on the renin-angiotensin-aldosterone system in normal rats. Eur J Pharmacol. 1980;62:269-275.
49. Kohara K, Brosnihan KB, Ferrario CM, Milsted A. Peripheral and central angiotensin II regulates expression of genes of the renin-angiotensin system. Am J Physiol. 1992;262:E651-E657.
50. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation. 1988; 77:14-13.
51. Iimura O, Shimamoto K. Role of kallikrein-kinin system in the hypotensive mechanisms of converting enzyme inhibitors in essential hypertension. J Cardiovasc Pharmacol. 1989;13(suppl. 3):S63-S66.
52. Jackson B, McGrath BP, Johnston CI. Correlation between angiotensin converting enzyme inhibition and the acute hypothensive response to MK 421 in essential hypertension. Clin Exp Pharmacol Physiol. 1982; 7(suppl):99-104.
53. Parving H-H, Larsen M, Hommel E, Lund-Andersen H. Effect of antihypertensive treatment on blood-retinal barrier permeability to fluorescein in hypertensive type 1 (insulin-dependent) diabetic patients with background retinopathy. Diabetologia. 1989;32:440-444.
54. +-ATPase activity in rabbit aorta by hyperglycemia. J Clin Invest. 1992;90:727-732.
55. Bonner G, Preis S, Schunk U, Toussaint C, Kaufmann W. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiavasc Pharmacol. 1990;15(suppl 6):S46-S56.
56. Mombouli J-V, Vanhoutte PM. Kinins and endothelium-dependent relaxations to converting enzyme inhibitors in perfused canine arteries. J Cardiovasc Pharmacol. 1991;18:926-927.
57. Torlone E, Britta M, Rambotti AM, et al. Improved insulin action and glycemic control after long-term angiotensin-converting enzyme inhibition in subjects with arterial hypertension and type II diabetes. Diabetes Care. 1993;16:1347-1355.
58. Alkarouf J, Nalinikumari K, Corry D, Tuck M. Long-term effects of angiotensin converting enzyme inhibitor captopril on metabolic control in non-insulin-dependent diabetes mellitus. Am J Hypertens. 1993;6:337-343.
59. Cohen MP, Klepser H, Shapiro E. Insulin stimulates renal glomerular sodium-potassium adenosine triphosphate activity. Biochem Biophys Acta. 1986;856: 182-184.
60. +-ATPase. J Biol Chem. 1985;260: 10075-10080.
61. Goldschmidt JE, Tallarida RJ. Pharmacological evidence that captopril possesses an endothelium-mediated component of vasodilation: Effect of sulfhydryl groups on endothelium-derived relaxing factor. J Pharmacol Exp Ther. 1991;257:1136-1145.
62. Vanhoutte PM, Auch-Schwelk W, Biondi ML, Lorenz RR, Schini VB, Vidai MJ. Why are converting enzyme inhibitors vasodilators? Br J Clin Pharmacol. 1989; 28:95S-104S.
63. Santoro FM, de la Riva IJ. Effect of captopril on Na,K-ATPase and Mg ATPase activities of erythrocytes ghost membranes. Pharmacol Res Commun. 1985;17:323-330.
64. +-ATPase. Clin Physiol Biochem. 1989;7:101-108.